Mallinckrodt plc provided earnings guidance for its fiscal year ending September 25, 2015. For fiscal 2015, Mallinckrodt's annual net sales are expected to be in the range of $3.65 billion to $3.75 billion on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates. Net sales for the company's Specialty Pharmaceutical segment are expected to be in the range of $2.87 billion to $2.92 billion.

This forecast includes full fiscal year net sales contributions from H.P. Acthar(R) Gel and OFIRMEV(R), two leading branded products in its Specialty Pharmaceuticals segment. Net sales for the company's Global Medical Imaging segment are expected to be in the range of $760 million to $800 million. Mallinckrodt expects adjusted diluted earnings per share (EPS) to be in the range of $6.70 to $7.20 for fiscal 2015.

This range reflects a weighted average, diluted share count of approximately 118 million. The non-GAAP effective tax is expected to be between 20% and 23%. Capital expenditures are forecasted to be in the range of $130 million to $150 million.